Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | RHOA | P61586 | 5/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17728991 | 0.93 | RHOA (0.60) | CNR1RAB9ARHOAALDH1A1LMNA | |
| SCHEMBL17773257 | 0.83 | RHOA (0.55) | RAB9ARHOAMEN1KMT2ATP53BP1 | |
| SCHEMBL12789540 | 0.78 | CNR1 (0.77) | CNR1RAB9AALDH1A1MEN1LMNA | |
| SCHEMBL17773237 | 0.78 | RAB9A (0.52) | RAB9ARHOAALDH1A1POLBTP53BP1 | |
| SCHEMBL6006050 | 0.75 | CNR1 (0.61) | CNR1RAB9AALDH1A1MEN1LMNA | |
| SCHEMBL3456305 | 0.74 | CNR1 (0.66) | CNR1RAB9AALDH1A1MEN1LMNA | |
| SCHEMBL17729073 | 0.74 | RHOA (0.61) | RHOAALDH1A1LMNAMAPTPOLB | |
| SCHEMBL25668693 | 0.74 | RAB9A (0.72) | RAB9ARHOAALDH1A1MAPTPOLB | |
| SCHEMBL17773205 | 0.74 | RAB9A (0.54) | RAB9ARHOAALDH1A1MEN1KMT2A | |
| SCHEMBL12790042 | 0.73 | CNR1 (0.72) | CNR1ALDH1A1MEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160145251-A1 | INHIBITORS OF MYOCARDIN-RELATED TRANSCRIPTION FACTOR AND SERUM RESPONSE FACTOR (MRTF/SRF)-MEDIATED GENE TRANSCRIPTION AND METHODS FOR USE OF THE SAME | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY | 2016-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160145251-A1 | INHIBITORS OF MYOCARDIN-RELATED TRANSCRIPTION FACTOR AND SERUM RESPONSE FACTOR (MRTF/SRF)-MEDIATED GENE TRANSCRIPTION AND METHODS FOR USE OF THE SAME | SREBF1, SREBF2, BPTF | CNR1 4590/4885RAB9A 2184/4885RHOA 229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.